NY
Times
Both
articles by Katie Thomas and Charles Ornstein
Dr.
Craig B. Thompson, the chief executive of Memorial Sloan Kettering Cancer
Center, resigned his seats on the boards of drug maker Merck and another public
company, the latest fallout from a widening institutional reckoning over
relationships between cancer center leaders and for-profit health care
companies
He received $300,000 in compensation from Merck in 2017,
according to company financial filings. He was paid $70,000 in cash by Charles
River in 2017, plus $215,050 in stock.
In 2016, he received $6.7 million in total compensation from
the hospital and related organizations, according to the most recent Internal
Revenue Service filings.
He keeps his job at
Sloan Kettering and gets a slap on the wrist.
How do these industry ties impact on patient care? MSKCC is a sorry
spectacle.
Also see: Case of Dr. José
Baselga, a towering figure in the cancer world, and the chief medical officer
at Memorial Sloan Kettering Cancer Center in New York. NY Times September 8, 2018.
No comments:
Post a Comment